Verona to test COPD hopeful ensifentrine in COVID-19 patientsVerona Pharma is starting a pilot study of its inhaled respiratory diseases drug ensifentrine in patients hospitalised with Share XVerona to test COPD hopeful ensifentrine in COVID-19 patientshttps://pharmaphorum.com/news/verona-to-test-copd-hopeful-ensifentrine-in-covid-19-patients/
Verona says FDA backs plan to take COPD drug into phase 3More than two years after first saying it would take its lead drug into a pivotal trial, Verona Share XVerona says FDA backs plan to take COPD drug into phase 3https://pharmaphorum.com/news/verona-says-fda-backs-plan-to-take-copd-drug-into-phase-3/
COPD: the world’s biggest neglected disease?We speak to Verona Pharma’s CEO Jan-Anders Karlsson to find out how the company is looking to tackle Share XCOPD: the world’s biggest neglected disease?https://pharmaphorum.com/r-d/views-analysis-r-d/copd-the-worlds-biggest-neglected-disease/
Verona pushes on with COPD drug after £70m fundraiserUK biotech hopes RPL554 could be a disease modifying drug. Share XVerona pushes on with COPD drug after £70m fundraiserhttps://pharmaphorum.com/news/verona-copd-ipo/
Are biotech IPOs back in fashion?After a slow first quarter, biotech IPOs may finally start to come into vogue in the coming months Share XAre biotech IPOs back in fashion?https://pharmaphorum.com/news/biotech-ipos-coming-back-fashion/